Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its novel DMT-based synthetic compound.

Conducted at Hammersmith Medicines Research Ltd. in the U.K., the study aims to contrast the safety and tolerability of its proprietary SPL026 compound delivered through IM and IV routes in up to 14 healthy participants.

Small Pharma CSO Carol Routledge explained that IM injection of SPL026 may provide greater convenience for physicians and improve patients’ experience.

See also: Analyzing …

Full story available on Benzinga.com